Paul Chaplin, Bavarian Nordic CEO

Bavar­i­an Nordic nets ma­jor vac­cine con­tract to re­spond to mon­key­pox out­break

The cur­rent mon­key­pox out­break is now at a phase where some gov­ern­ments are ap­proach­ing a point of con­cern, at least enough to start stock­pil­ing vac­cines.

In re­sponse, at least one gov­ern­ment is plac­ing its or­der with vac­cine man­u­fac­tur­er Bavar­i­an Nordic to se­cure suf­fi­cient sup­ply for vac­ci­nat­ing in­di­vid­u­als. Ac­cord­ing to the com­pa­ny, it has inked a sup­ply con­tract with an undis­closed coun­try for the com­pa­ny’s small­pox vac­cine, called Jyn­neos. The aim is to en­sure there will be enough sup­ply to meet the undis­closed coun­try’s re­quire­ments for vac­ci­nat­ing in­di­vid­u­als at risk for mon­key­pox in the short to medi­um term. The vac­cine is ap­proved for use against mon­key­pox by the FDA and Health Cana­da.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters